CRS1 Stock Overview
Manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals in Spain. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Ercros, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.45 |
| 52 Week High | €3.91 |
| 52 Week Low | €2.26 |
| Beta | 0.71 |
| 11 Month Change | -4.70% |
| 3 Month Change | -7.26% |
| 1 Year Change | 42.27% |
| 33 Year Change | 21.05% |
| 5 Year Change | 48.84% |
| Change since IPO | -61.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| CRS1 | DE Chemicals | DE Market | |
|---|---|---|---|
| 7D | -0.9% | -0.1% | 1.3% |
| 1Y | 42.3% | -0.3% | 7.9% |
Return vs Industry: CRS1 exceeded the German Chemicals industry which returned -0.3% over the past year.
Return vs Market: CRS1 exceeded the German Market which returned 7.9% over the past year.
Price Volatility
| CRS1 volatility | |
|---|---|
| CRS1 Average Weekly Movement | 2.3% |
| Chemicals Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CRS1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: CRS1's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1817 | 1,359 | Antonio Zabalza Marti | www.ercros.es |
Ercros, S.A. manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals in Spain. It operates through three segments: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment produces ammonia, bioplastics, caustic potash and soda, chlorine, chloroisocyanurates, dicalcium phosphate, dichloroethane, hydrochloric acid, hydrogen peroxide, potassium carbonate, PVC compounds, sodium chlorate and chlorite, sodium hypochlorite, and vinyl chloride monomers and polychloride.
Ercros, S.A. Fundamentals Summary
| CRS1 fundamental statistics | |
|---|---|
| Market cap | €322.31m |
| Earnings (TTM) | €14.10m |
| Revenue (TTM) | €656.52m |
22.9x
P/E Ratio0.5x
P/S RatioIs CRS1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRS1 income statement (TTM) | |
|---|---|
| Revenue | €656.52m |
| Cost of Revenue | €463.93m |
| Gross Profit | €192.60m |
| Other Expenses | €178.49m |
| Earnings | €14.10m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.15 |
| Gross Margin | 29.34% |
| Net Profit Margin | 2.15% |
| Debt/Equity Ratio | 42.5% |
How did CRS1 perform over the long term?
See historical performance and comparison